Long-term efficacy and safety of fourth-line multikinase inhibitor treatment with lenvatinib in a young papillary thyroid carcinoma patient

Long-term efficacy and safety of fourth-line multikinase inhibitor treatment with lenvatinib in a young papillary thyroid carcinoma patient

Article Page

Abstract
Lenvatinib, a multikinase inhibitor, is approved for the treatment of patients with radioiodine-refractory metastatic thyroid cancer on the basis of a Phase III, prospective, double-blind, randomized, placebo-controlled trial that showed longer progression-free survival in the drug-treated arm. Here, we report the case of a young papillary thyroid cancer patient, pretreated with three other kinase inhibitors, who achieved a long-term clinical benefit from lenvatinib in the fourth-line setting.

Keywords: lenvatinib, papillary thyroid carcinoma, poorly differentiated thyroid carcinoma, RAI refractory, sorafenib, sunitinib.

Abbreviations: CT, computed tomography; MRI, magnetic resonance imaging; PET, positron emission tomography; TKI, tyrosine kinase inhibitor

Citation: Morelli S, Puxeddu E. Long-term efficacy and safety of fourth-line multikinase inhibitor treatment with lenvatinib in a young papillary thyroid carcinoma patient. Drugs in Context 2017; 6: 212310. DOI: 10.7573/dic.212310

Disclosure and potential conflicts of interest: The authors have declared no conflicts of interest. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interest form for the authors are available for download at http://www.drugsincontext.com/wp-content/uploads/2017/07/dic.212310-COI.pdf.

Acknowledgments: All authors have contributed to the article and have read and approved the final version of the manuscript, which has not been previously published and is not under consideration by any other journal.

Copyright: Copyright © 2017 Morelli S, Puxeddu E. Distributed under the terms of the Creative Commons License Deed CC BY 3.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2017 Morelli S, Puxeddu E. https://doi.org/10.7573/dic.212310. Published by Drugs in Context under Creative Commons License Deed CC BY 3.0.

Article URL: http://www.drugsincontext.com/long-term-efficacy-safety-fourth-line-multikinase-inhibitor-treatment-lenvatinib-young-papillary-thyroid-carcinoma-patient

Correspondence: Efisio Puxeddu, MD, PhD, Dipartimento di Medicina, Università degli Studi di Perugia, Edificio D, piano +2, Piazza L. Severi 1, 06132 Perugia, Italy. efisio.puxeddu@unipg.it

Provenance: submitted; externally peer reviewed

Submitted: 7 June 2017; Peer review comments to author: 16 June 2017; Revised manuscript received: 27 June 2017; Accepted: 29 June 2017; Publication: 17 July 2017

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: 14 Weller Street, London, SE1 1QU, UK

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252772009.

For all manuscript and submissions enquiries, contact the Editorial office dic.editorial@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF

Resources